ATE469921T1 - Lpa-haltige verbindungen - Google Patents

Lpa-haltige verbindungen

Info

Publication number
ATE469921T1
ATE469921T1 AT04739024T AT04739024T ATE469921T1 AT E469921 T1 ATE469921 T1 AT E469921T1 AT 04739024 T AT04739024 T AT 04739024T AT 04739024 T AT04739024 T AT 04739024T AT E469921 T1 ATE469921 T1 AT E469921T1
Authority
AT
Austria
Prior art keywords
compounds
amino acid
fgfr
acid sequences
lpa
Prior art date
Application number
AT04739024T
Other languages
English (en)
Inventor
Morten Albrechtsen
Elisabeth Bock
Vladimir Berezin
Arne Holm
Original Assignee
Enkam Pharmaceuticals As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enkam Pharmaceuticals As filed Critical Enkam Pharmaceuticals As
Application granted granted Critical
Publication of ATE469921T1 publication Critical patent/ATE469921T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
AT04739024T 2003-08-07 2004-08-06 Lpa-haltige verbindungen ATE469921T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200301141 2003-08-07
DKPA200400814 2004-05-25
PCT/DK2004/000527 WO2005014623A2 (en) 2003-08-07 2004-08-06 Compounds comprising lpa

Publications (1)

Publication Number Publication Date
ATE469921T1 true ATE469921T1 (de) 2010-06-15

Family

ID=34137357

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04739024T ATE469921T1 (de) 2003-08-07 2004-08-06 Lpa-haltige verbindungen

Country Status (11)

Country Link
US (1) US20090105149A1 (de)
EP (1) EP1660539B1 (de)
JP (1) JP2007526898A (de)
AT (1) ATE469921T1 (de)
AU (1) AU2004263203A1 (de)
BR (1) BRPI0413373A (de)
CA (1) CA2534355A1 (de)
DE (1) DE602004027508D1 (de)
IL (1) IL173532A0 (de)
MX (1) MXPA06001501A (de)
WO (1) WO2005014623A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2457164A1 (en) * 2001-08-17 2003-02-27 Enkam Pharmaceuticals A/S Compounds capable of affecting differentiation, proliferation, regeneration, plasticity and survival of cells
AU2004275929A1 (en) * 2003-09-30 2005-04-07 Enkam Pharmaceuticals A/S A method of modulating cell survival, differentiation and/or synaptic plasticity
ES2660765T3 (es) 2004-06-21 2018-03-26 The Board Of Trustees Of The Leland Stanford Junior University Genes y rutas expresadas de forma diferencial en trastorno bipolar y/o trastorno depresivo mayor
EP2564864B8 (de) * 2005-11-12 2015-05-13 The Board of Trustees of The Leland Stanford Junior University Verfahren im Zusammenhang mit FGF2 zur Diagnose und Behandlung von Depressionen
CN101384542B (zh) 2006-02-14 2012-07-04 巴斯夫欧洲公司 由单乙二醇(meg)生产亚乙基胺和乙醇胺的方法
WO2007093177A2 (en) 2006-02-14 2007-08-23 Vladimir Berezin Metallothionein-derived peptide fragments
US7635790B2 (en) 2006-02-14 2009-12-22 Basf Se Method for producing ethylene amines and ethanol amines by the hydrogenating amination of monoethylene glycol and ammonia in the presence of a catalyst
EP2120967B1 (de) * 2006-11-28 2015-10-21 University Of Southern California Verfahren zur förderung der wundheilung
WO2009068042A2 (en) * 2007-11-28 2009-06-04 Enkam Pharmaceuticals A/S Novel peptides derived from ncam (fgls)
WO2009100724A1 (en) * 2008-02-11 2009-08-20 Kobenhavns Universitet Novel peptide derived from ncam (bcl)
CN102639700A (zh) 2009-09-30 2012-08-15 哈佛大学校长及研究员协会 通过调节自噬增强基因产物调节自噬的方法
WO2013184824A1 (en) * 2012-06-05 2013-12-12 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating psychiatric disorders or symptoms thereof using ncam peptide mimetics
US11229789B2 (en) 2013-05-30 2022-01-25 Neurostim Oab, Inc. Neuro activator with controller
EP3441109A1 (de) 2013-05-30 2019-02-13 Graham H. Creasey Flexibles hautpflaster für ein stimulatorsystem für topische nerven
US11077301B2 (en) 2015-02-21 2021-08-03 NeurostimOAB, Inc. Topical nerve stimulator and sensor for bladder control
SI3464336T1 (sl) 2016-06-01 2022-06-30 Athira Pharma, Inc. Spojine
EP3706856A4 (de) 2017-11-07 2021-08-18 Neurostim Oab, Inc. Nicht-invasiver nervenaktivator mit adaptiver schaltung
US11458311B2 (en) 2019-06-26 2022-10-04 Neurostim Technologies Llc Non-invasive nerve activator patch with adaptive circuit
EP4017580A4 (de) 2019-12-16 2023-09-06 Neurostim Technologies LLC Nicht-invasiver nervenaktivator mit verstärkter ladungsabgabe

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5629291A (en) * 1992-01-31 1997-05-13 La Jolla Cancer Research Foundation Methods of modulating fibronectin extracellular matrix assembly
US5840689A (en) * 1993-10-29 1998-11-24 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Method for stimulating the regrowth of neurons
US5693488A (en) * 1994-05-12 1997-12-02 The Rockefeller University Transmembrane tyrosine phosphatase, nucleic acids encoding the same, and methods of use thereof
US6576607B1 (en) * 1995-04-19 2003-06-10 Acorda Therapeutics Methods using CNS neurite outgrowth modulators
US6313265B1 (en) * 1995-07-24 2001-11-06 The Scripps Research Institute Neurite outgrowth-promoting polypeptides containing fibronectin type III repeats and methods of use
AU6078399A (en) * 1998-09-29 2000-04-17 Arne Holm Ligand presenting assembly (lpa), method of preparation and uses thereof
US7504490B1 (en) * 1998-10-16 2009-03-17 Oscient Pharmaceuticals Corporation Nucleic acid and amino acid sequences relating to Apergillus fumigatus for diagnostics and therapeutics
US7167819B1 (en) * 1999-05-26 2007-01-23 Chiron Corporation Method of determining the three-dimensional shape of a macromolecule
US6749850B1 (en) * 1999-08-18 2004-06-15 The General Hospital Corporation Methods, compositions and kits for promoting recovery from damage to the central nervous system
WO2001016166A2 (en) * 1999-08-27 2001-03-08 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Polypeptides, comprising il-6 ligand-binding receptor domains, and related nucleic acids, antibodies, compositions, and methods of use
WO2002047719A2 (en) * 2000-12-12 2002-06-20 Enkam Pharmaceuticals A/S Survical promoting ncam binding and ncam ligand biding compounds
CA2457164A1 (en) * 2001-08-17 2003-02-27 Enkam Pharmaceuticals A/S Compounds capable of affecting differentiation, proliferation, regeneration, plasticity and survival of cells
EP1436318A2 (de) * 2001-09-05 2004-07-14 Enkam Pharmaceuticals A/S Ncam-bindende verbindungen
CA2510715A1 (en) * 2002-12-20 2004-07-08 Enkam Pharmaceuticals A/S Method of modulation of interaction between receptor and ligand

Also Published As

Publication number Publication date
IL173532A0 (en) 2006-07-05
EP1660539A2 (de) 2006-05-31
AU2004263203A1 (en) 2005-02-17
JP2007526898A (ja) 2007-09-20
BRPI0413373A (pt) 2006-10-17
US20090105149A1 (en) 2009-04-23
WO2005014623A2 (en) 2005-02-17
CA2534355A1 (en) 2005-02-17
WO2005014623A3 (en) 2005-09-09
MXPA06001501A (es) 2006-09-04
EP1660539B1 (de) 2010-06-02
DE602004027508D1 (de) 2010-07-15

Similar Documents

Publication Publication Date Title
DE602004027508D1 (de) Lpa-haltige verbindungen
ATE384526T1 (de) N-(((((1,3-thiazol-2- yl)amino)carbonyl)phenyl)sulphonyl)phenylalanin derivate und verwandte verbindungen zur behandlung von diabetes
CL2003001743A1 (es) Compuestos derivados de leucinamida, inhibidores de la cisteina proteasa; composicion farmaceutica; procedimiento de preparacion de la composicion farmaceutica; y su uso en el tratamiento de la osteoporosis, enfermedad de paget's, peridontal, perdida
BRPI0415288B8 (pt) composição farmacêutica compreendendo o ácido 1-{[(a- isobutanoiloxietoxi) carbonil] aminometil}- 1-ciclo- hexano acético cristalino
DE60311820D1 (de) Neue verwendung von pyrimidin- oder triazin-2-carbonsäurenitrilen zur behandlung von krankheiten, die mit cysteinproteaseaktivität assoziiert sind, und neue pyridimidin-2-carbonsäurenitrilderivate
ATE382364T1 (de) Von igf-bindungsprotein stammendes peptid
DE60319066D1 (de) 1,4-disubstituierte benzokondensierte cycloalkyl-harnstoffverbindungen zur behandlung von zytokinvermittelten erkrankungen
EP2311851A3 (de) Inhibitoren der Serinproteasen, insbesondere der HCV-NS3-NS4A-Protease
WO2005023866A3 (en) Peptides that inhibit complement activation
WO2007125210A8 (fr) Utilisation de ligands synthetiques multivalents de la nucleoline de surface pour le traitement du cancer ou de l'inflammation
WO2007024651A3 (en) Bridged n-bicyclic sulfonamido inhibitors of gamma secretase
ATE491463T1 (de) Verfahren zur herstellung von alpha (2) makroglobulin-antigen-molekül-komplexen
ATE534736T1 (de) Identifizierungsverfahren und verbindungen für die behandlung degenerativer und entzündlicher erkrankungen
NO20075227L (no) Treatment of eczemas
DK1561754T3 (da) Fremgangsmåde til fremstilling af 1,2-diaminocyclohexanplatin(II)-komplekser
TW200633977A (en) Novel process for the manufacture of 3-pyrrolidin-2-yl-propionic acid derivatives
ATE545655T1 (de) Fgfr-bindende peptide
DE602004017512D1 (de) Neues peptid, verfahren zu dessen herstellung und pharmazeutische zusammensetzung, die das peptid enthält
ATE410437T1 (de) Verfahren und systeme zur rückgewinnung von peptiden
ATE301127T1 (de) Ferrocenylliganden und ein verfahren zur herstellung solcher liganden
DK1778623T3 (da) Derivater af 1-phenylalkancarboxylsyrer til behandling af neurodegenerative sygdomme
ATE533776T1 (de) Analoge verbindungen analgetischer peptide, abgeleitet vom crotalus durissus terrificus schlangengift, ihre verwendungen, zusammensetzungen und verfahren ihrer herstellung und reinigung
DE60235505D1 (de) Neues verfahren und neue zusammensetzung zur hemmurwendung von verbindungen auf basis einer sequenz in mmp-2
ATE503476T1 (de) Zusammensetzungen und verfahren zur behandlung von krankheiten, die durch infektion mit yersinia spp ausgelöst sind
ATE505193T1 (de) Arzneimittelkombinationen zur behandlung von atemwegserkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties